JAK2 and diabetic kidney disease: Treatment with the selective JAK1 and JAK2 inhibitor baricitinib resulted in a dose-dependent decrease in albuminuria, indicating a potential benefit of JAK1/JAK2 inhibitors as a new therapy for DKD patients (Tuttle et al. 2018).